Afinitor Disperz — CareFirst (Caremark)
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent unresectable, advanced, or metastatic breast cancer
Initial criteria
- Prescribed in combination with exemestane, fulvestrant, or tamoxifen
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months